Skip to main content
Top
Published in: European Radiology 6/2009

Open Access 01-06-2009 | Neuro

Tumour enhancing fraction (EnF) in glioma: relationship to tumour grade

Authors: Samantha J. Mills, Calvin Soh, James P. B. O’Connor, Chris J. Rose, Giovanni A. Buonaccorsi, Susan Cheung, Sha Zhao, Geoff J. M. Parker, Alan Jackson

Published in: European Radiology | Issue 6/2009

Login to get access

Abstract

The aim of this research was to determine whether the proportion of a tumour that enhances (enhancing fraction, EnF) and changes in EnF with enhancement threshold differ between low and high grade glioma. Forty-four patients (45 gliomas comprising 16 grade II, 5 grade III and 24 grade IV) were studied. Imaging included pre- and post-contrast-enhanced T1-weighted sequences and T1-weighted DCE-MRI. Thresholded enhancement maps were generated for each tumour by using a range of values of the initial area under the contrast concentration curve (IAUC). A plot of EnF versus threshold value was generated. We examined the relationship between tumour grade and enhancement metrics including: EnF (threshold IAUC > 0 mMol s), EnF (threshold IAUC > 2.5 mMol s), initial slope of the EnF/threshold curve (∂EnF), IAUC, and two previously described signal-intensity-based metrics. EnF, defined as the proportion of tumour showing any enhancement (threshold IAUC > 0 mMol s), showed no difference between low and high grade glioma. All other measures demonstrated significant differences between grade II and IV, and low (grade II) and high grade (grades III/ IV) gliomas (p < 0.01). Two measures, ∂EnF and Pronin’s measure of enhancement, showed differences between grade III and IV (p < 0.05). No measure separated grade II from III. Metrics which describe the enhancing fraction and its variation with enhancement threshold ∂EnF show considerably different behaviour in low and high grade tumours. These observations suggest that these metrics may provide important biological information concerning tumour biology and therapeutic responses and encourage further research to characterise and validate these novel biomarkers.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lopes MBS (2005) Neuropathology. In: Schiff D, O’Neill BP (eds) Principles of neuro-oncology. McGraw-Hill, New York, pp 81–120 Lopes MBS (2005) Neuropathology. In: Schiff D, O’Neill BP (eds) Principles of neuro-oncology. McGraw-Hill, New York, pp 81–120
2.
go back to reference Winkler F, Kozin SV, Tong RT et al (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6:553–563PubMed Winkler F, Kozin SV, Tong RT et al (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6:553–563PubMed
3.
go back to reference Jayson GC, Parker GJ, Mullamitha S et al (2005) Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab’, leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 23:973–981PubMedCrossRef Jayson GC, Parker GJ, Mullamitha S et al (2005) Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab’, leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 23:973–981PubMedCrossRef
4.
go back to reference Mullamitha SA, Ton NC, Parker GJ et al (2007) Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res 13:2128–2135PubMedCrossRef Mullamitha SA, Ton NC, Parker GJ et al (2007) Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res 13:2128–2135PubMedCrossRef
5.
go back to reference O’Connor JP, Jayson GC, Jackson A et al (2007) Enhancing fraction predicts clinical outcome following first-line chemotherapy in patients with epithelial ovarian carcinoma. Clin Cancer Res 13:6130–6135PubMedCrossRef O’Connor JP, Jayson GC, Jackson A et al (2007) Enhancing fraction predicts clinical outcome following first-line chemotherapy in patients with epithelial ovarian carcinoma. Clin Cancer Res 13:6130–6135PubMedCrossRef
6.
7.
go back to reference Aronen HJ, Gazit IE, Louis DN et al (1994) Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 191:41–51PubMed Aronen HJ, Gazit IE, Louis DN et al (1994) Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 191:41–51PubMed
8.
go back to reference Haroon HA, Patankar TA, Dow G et al (2002) Relationship between vasculoar endothelial permeability and histological grade in human gliomas using a novel first pass model. In: Proceedings of the 10th international meeting of the nternational Society for Magnetic Resonance in Medicine, Honolulu, Hawaii, May 2002, p 2113 Haroon HA, Patankar TA, Dow G et al (2002) Relationship between vasculoar endothelial permeability and histological grade in human gliomas using a novel first pass model. In: Proceedings of the 10th international meeting of the nternational Society for Magnetic Resonance in Medicine, Honolulu, Hawaii, May 2002, p 2113
9.
go back to reference Patankar TF, Haroon HA, Mills SJ et al (2005) Is volume transfer coefficient (K(trans)) related to histologic grade in human gliomas? AJNR Am J Neuroradiol 26:2455–2465PubMed Patankar TF, Haroon HA, Mills SJ et al (2005) Is volume transfer coefficient (K(trans)) related to histologic grade in human gliomas? AJNR Am J Neuroradiol 26:2455–2465PubMed
10.
go back to reference Barker FG 2nd, Chang SM, Huhn SL et al (1997) Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer 80:936–941PubMedCrossRef Barker FG 2nd, Chang SM, Huhn SL et al (1997) Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer 80:936–941PubMedCrossRef
11.
go back to reference Hammoud MA, Sawaya R, Shi W et al (1996) Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol 27:65–73PubMedCrossRef Hammoud MA, Sawaya R, Shi W et al (1996) Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol 27:65–73PubMedCrossRef
12.
go back to reference Pronin IN, Holodny AI, Kornienko VN et al (1997) The use of hyperventilation in contrast-enhanced MR of brain tumors. AJNR Am J Neuroradiol 18:1705–1708PubMed Pronin IN, Holodny AI, Kornienko VN et al (1997) The use of hyperventilation in contrast-enhanced MR of brain tumors. AJNR Am J Neuroradiol 18:1705–1708PubMed
13.
go back to reference Pronin IN, Holodny AI, Petraikin AV (1997) MRI of high-grade glial tumors: correlation between the degree of contrast enhancement and the volume of surrounding edema. Neuroradiology 39:348–350PubMedCrossRef Pronin IN, Holodny AI, Petraikin AV (1997) MRI of high-grade glial tumors: correlation between the degree of contrast enhancement and the volume of surrounding edema. Neuroradiology 39:348–350PubMedCrossRef
14.
go back to reference White ML, Zhang Y, Kirby P et al (2005) Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas? AJNR Am J Neuroradiol 26:784–790PubMed White ML, Zhang Y, Kirby P et al (2005) Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas? AJNR Am J Neuroradiol 26:784–790PubMed
15.
go back to reference Tofts PS, Benton CE, Weil RS et al (2007) Quantitative analysis of whole-tumor Gd enhancement histograms predicts malignant transformation in low-grade gliomas. J Magn Reson Imaging 25:208–214PubMedCrossRef Tofts PS, Benton CE, Weil RS et al (2007) Quantitative analysis of whole-tumor Gd enhancement histograms predicts malignant transformation in low-grade gliomas. J Magn Reson Imaging 25:208–214PubMedCrossRef
16.
go back to reference Evelhoch JL (1999) Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 10:254–259PubMedCrossRef Evelhoch JL (1999) Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 10:254–259PubMedCrossRef
17.
go back to reference Parker GJM, Buckley DL (2005) Tracer kinetic modelling for T1-weighted DCE-MRI. In: Jackson A, Buckley DL, Parker GJM (eds) Dynamic contrast-enhanced magnetic resonance imaging in oncology. Springer, Berlin, pp 81–92CrossRef Parker GJM, Buckley DL (2005) Tracer kinetic modelling for T1-weighted DCE-MRI. In: Jackson A, Buckley DL, Parker GJM (eds) Dynamic contrast-enhanced magnetic resonance imaging in oncology. Springer, Berlin, pp 81–92CrossRef
18.
go back to reference Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (Berl) 114:97–109CrossRef Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (Berl) 114:97–109CrossRef
19.
go back to reference Haase A (1990) Snapshot FLASH MRI. Applications to T1, T2, and chemical-shift imaging. Magn Reson Med 13:77–89PubMedCrossRef Haase A (1990) Snapshot FLASH MRI. Applications to T1, T2, and chemical-shift imaging. Magn Reson Med 13:77–89PubMedCrossRef
20.
go back to reference Buckley DL, Parker GJM (2005) Measuring contrast agent concentration in T1-weighted dynamic contrast enhanced MRI. In: Jackson A, Buckley DL, Parker GJM (eds) Dynamic contrast-enhanced magnetic resonance imaging in oncology. Springer, Berlin, p 69CrossRef Buckley DL, Parker GJM (2005) Measuring contrast agent concentration in T1-weighted dynamic contrast enhanced MRI. In: Jackson A, Buckley DL, Parker GJM (eds) Dynamic contrast-enhanced magnetic resonance imaging in oncology. Springer, Berlin, p 69CrossRef
21.
go back to reference Cha S, Lupo JM, Chen MH et al (2007) Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol 28:1078–1084PubMedCrossRef Cha S, Lupo JM, Chen MH et al (2007) Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol 28:1078–1084PubMedCrossRef
Metadata
Title
Tumour enhancing fraction (EnF) in glioma: relationship to tumour grade
Authors
Samantha J. Mills
Calvin Soh
James P. B. O’Connor
Chris J. Rose
Giovanni A. Buonaccorsi
Susan Cheung
Sha Zhao
Geoff J. M. Parker
Alan Jackson
Publication date
01-06-2009
Publisher
Springer-Verlag
Published in
European Radiology / Issue 6/2009
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-008-1288-z

Other articles of this Issue 6/2009

European Radiology 6/2009 Go to the issue